Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction has emerged as a powerful strategy in cancer immunotherapy. Recently, there have been enormous efforts to develop potent PD-1/PD-L1 inhibitors. In particular, Bristol-Myers Squibb (BMS) and Aurigene Discovery Technologies have individually disclosed several promising PD-1/PD-L1 inhibitors, whose detailed experimental data are not publicly disclosed. In this work, we report the rigorous and systematic in vitro characterization of a selected set of potent PD-1/PD-L1 macrocyclic peptide (BMSpep-57) and small-molecule inhibitors (BMS-103, BMS-142) from BMS and a peptidomimetic small-molecule inhibitor from Aurigene (Aurigene-1) using a series of biochemical and cell-based assays. Our results confirm that BMS-103 and BMS-142 are strongly active in biochemical assays; however, their acute cytotoxicity greatly compromised their immunological activity. On the other hand, Aurigene-1 did not show any activity in both biochemical and immunological assays. Furthermore, we also report the discovery of a small-molecule immune modulator, whose mode-of-action is not clear; however, it exhibits favorable drug-like properties and strong immunological activity. We hope that the results presented here will be useful in guiding the development of next-generation PD-1/PD-L1 small molecule inhibitors.

[1]  W. Coley,et al.  Contribution To The Knowledge Of Sarcoma , 1891 .

[2]  A. Kupfer,et al.  T-cell effector functions: mechanisms for delivery of cytotoxicity and help. , 1991, Annual review of cell biology.

[3]  J. Grant.  Promise and progress , 1995 .

[4]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[6]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[7]  N A Mitchison,et al.  Tolerance and Autoimmunity , 2001 .

[8]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Abbas,et al.  The enemy within: keeping self-reactive T cells at bay in the periphery , 2002, Nature Reviews Immunology.

[10]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[11]  G. Holdgate,et al.  Measurements of binding thermodynamics in drug discovery. , 2005, Drug discovery today.

[12]  S. Romagnani.  Immunological tolerance and autoimmunity , 2006, Internal and emergency medicine.

[13]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[14]  T. Mayadas,et al.  Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles1 , 2007, The Journal of Immunology.

[15]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[16]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[17]  T. Strutt,et al.  Control of innate immunity by memory CD4 T cells. , 2011, Advances in experimental medicine and biology.

[18]  Yuanguo Cheng,et al.  Qualitative and quantitative studies on human B7.1-Fc fusion protein and the application in pharmacokinetic study in rhesus monkeys. , 2011, Journal of pharmaceutical and biomedical analysis.

[19]  Dieter Braun,et al.  Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.

[20]  Kristen E. Pauken,et al.  The role of the PD‐1 pathway in autoimmunity and peripheral tolerance , 2011, Annals of the New York Academy of Sciences.

[21]  F. Pan,et al.  T Cell Signaling Targets for Enhancing Regulatory or Effector Function , 2012, Science Signaling.

[22]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[23]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[24]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[25]  A. Cuconati,et al.  Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation , 2012, Antimicrobial Agents and Chemotherapy.

[26]  E. Wherry,et al.  Inhibitory Receptors on Lymphocytes: Insights from Infections , 2012, The Journal of Immunology.

[27]  John E. Ladbury,et al.  Structure and Interactions of the Human Programmed Cell Death 1 Receptor* , 2013, The Journal of Biological Chemistry.

[28]  Carlos Simmerling,et al.  Improved Generalized Born Solvent Model Parameters for Protein Simulations. , 2013, Journal of chemical theory and computation.

[29]  M. Pellecchia,et al.  NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein–Protein Interactions , 2014, Chemical reviews.

[30]  Xiumin Wang,et al.  PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients , 2014, Cancer Immunology, Immunotherapy.

[31]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[32]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[33]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[34]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[35]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2017, Cell.

[36]  K. Zak,et al.  Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1) , 2016, Oncotarget.

[37]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[38]  K. Zak,et al.  Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015) , 2016, Expert opinion on therapeutic patents.

[39]  Chenzhong Liao,et al.  From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. , 2016, Drug discovery today.

[40]  P. Ascierto,et al.  PD-L1 inhibitors in the pipeline: Promise and progress , 2018, Oncoimmunology.

[41]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[42]  L. S. Angelo,et al.  Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models , 2017, Front. Immunol..

[43]  Isobel S Okoye,et al.  Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer , 2017, Front. Immunol..

[44]  T. Holak,et al.  Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. , 2017, Journal of medicinal chemistry.

[45]  J. Infante,et al.  Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas. , 2017 .

[46]  L. Skalniak,et al.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. , 2017, Angewandte Chemie.

[47]  L. Skalniak,et al.  Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells , 2017, Oncotarget.

[48]  G. Freeman,et al.  Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function , 2018, The Journal of Immunology.

[49]  Katarzyna Guzik,et al.  A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018) , 2018, Expert opinion on therapeutic patents.

[50]  R. Satchi‐Fainaro,et al.  Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. , 2018, Journal of medicinal chemistry.

[51]  M. Ramachandra,et al.  Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways , 2018, BioDrugs.

[52]  Hakho Lee,et al.  Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles , 2018, Science Advances.

[53]  A. Ganesan,et al.  Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study. , 2018, Biochimica et biophysica acta. General subjects.

[54]  O. Dahl,et al.  The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018 , 2019, Acta oncologica.

[55]  Longqin Hu,et al.  Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules , 2018, Medicinal research reviews.

[56]  Fragment-based screening of programmed death ligand 1 (PD-L1). , 2019 .

[57]  E. Olejniczak,et al.  Fragment-based screening of programmed death ligand 1 (PD-L1). , 2019, Bioorganic & medicinal chemistry letters.

[58]  J. Chisholm,et al.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves , 2019, The Journal of Immunology.

[59]  Zilan Song,et al.  Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. , 2019, Current topics in medicinal chemistry.